Two independent peer-reviewed clinical studies validate remote Biophysical Profile assessment, supporting Pulsenmore’s strategy to expand its platform through scalable SaaS applications.
Ramat Gan, Israel, July 15, 2026 – Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced growing clinical evidence supporting the expansion of its home ultrasound platform beyond individual ultrasound measurements toward more advanced prenatal assessments.
Two independent peer-reviewed clinical studies, published in the International Journal of Gynecology & Obstetrics (IJGO) and AJOG MFM and conducted by leading medical centers in the United States and Israel, demonstrated that the ultrasound components of the Biophysical Profile (BPP), one of the most widely used fetal surveillance examinations during pregnancy, can be successfully performed using Pulsenmore’s home ultrasound platform under real-time clinician guidance.
Pulsenmore’s technology enables pregnant women to perform physician-prescribed ultrasound examinations at home using a compact ultrasound device connected to their own smartphone. Each examination is securely transmitted to a physician for remote review and clinical decision-making. To date, Pulsenmore’s platform has supported more than 250,000 home ultrasound examinations.
BPP is an established, reimbursed clinical examination widely used around the world. Approximately 10% of pregnancies require repeated antenatal fetal surveillance, and BPP is one of the most commonly used assessment tools for evaluating fetal well-being in pregnancies complicated by diabetes, fetal growth restriction, decreased fetal movements, and post-term pregnancy. Its recurring utilization and existing reimbursement pathways make BPP an attractive target for software-enabled remote care.
Two studies, led by Dr. Alex Peahl and colleagues at the University of Michigan and Prof. Eran Hadar and Dr. Anat Pardo at Rabin Medical Center, Israel, enrolled a total of 55 pregnant women. Both studies consistently demonstrated high agreement between home ultrasound examinations and conventional hospital-based assessments of the ultrasound components of the BPP, with strong concordance across fetal movement, fetal breathing, fetal tone, fetal presentation, fetal heart rate, and amniotic fluid assessment. The findings support the feasibility of performing this complex fetal surveillance examination remotely under clinician guidance.
Prof. Eran Hadar and Dr. Anat Pardo, the Beilinson study’s principal investigators, commented:
«For the first time, we demonstrated that a complex ultrasound examination can be performed remotely using a home ultrasound device operated by the pregnant woman herself, while maintaining high agreement with hospital-based examinations. This approach has the potential to improve access to maternal-fetal care, reduce unnecessary hospital visits, and become an important component of future digital pregnancy care.»
Dr. Alex Peahl, the University of Michigan study’s principal investigator, commented:
«The BPP4Me study is an important first step in making antenatal testing available for all patients, even those facing the greatest barriers to care.»
Together, these independent studies strengthen the clinical evidence supporting the expansion of Pulsenmore’s platform from individual ultrasound measurements to more comprehensive prenatal assessments. They also support the Company’s strategy of expanding the capabilities of its existing platform through dedicated software-based clinical applications, creating opportunities to introduce Software-as-a-Service (SaaS) modules that can expand Pulsenmore’s addressable market while increasing the value of its existing installed base.
Dr. Elazar Sonnenschein, Founder and CEO of Pulsenmore, said:
«Each validated clinical application strengthens the value of our platform for healthcare providers and expands our addressable market through a SaaS-driven strategy. We believe this approach unlocks new recurring revenue opportunities and positions us for sustained long-term growth.»
About Pulsenmore
Pulsenmore Ltd. is dedicated to revolutionizing maternal health through home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care.
For more information, visit www.pulsenmore.com.
Forward-Looking Statements
This press release contains forward-looking statements. In particular, statements using words such as «may,» «seek,» «will,» «consider,» «likely,» «assume,» «estimate,» «expect,» «anticipate,» «intend,» «believe,» «contemplate,» «do not believe,» «aim,» «goal,» «due,» «predict,» «plan,» «project,» «continue,» «potential,» «positioned,» «guidance,» «objective,» «outlook,» «trends,» «future,» «could,» «would,» «should,» «target,» «on track» or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding the Company’s strategy to expand its platform through software-based clinical applications, the potential development and commercialization of future SaaS modules, potential future regulatory clearances, anticipated market opportunities, expected adoption by healthcare providers, the expansion of the Company’s addressable market, future recurring revenue opportunities, and the Company’s long-term growth strategy. Forward-looking statements reflect Pulsenmore’s current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company’s lack of operating history; the Company’s current and future capital requirements and the Company’s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company’s ability to manufacture, market and sell its products and to generate revenues; the Company’s ability to maintain its relationships with key partners and grow relationships with new partners; the Company’s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company’s ability to launch and penetrate markets in new locations and new market segments; the Company’s ability to retain key executive members and hire additional personnel; the Company’s ability to maintain and expand intellectual property rights; interpretations of current laws and the passage of future laws; the Company’s ability to achieve greater regulatory compliance needed in existing and new markets; the Company’s ability to achieve key performance milestones in its planned operational testing; the Company’s ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company’s business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company’s Annual Report on Form 20-F, filed with the SEC on March 30, 2026. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.
Investor Contact:
Miri Segal-Scharia
MS-IR LLC
[email protected]
